Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Eylea to Treat Retinal Pigment Epithelial Detachment (RPED) Secondary to Wet Age-Related Macular Degeneration (wAMD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02142296
Recruitment Status : Completed
First Posted : May 20, 2014
Last Update Posted : February 16, 2017
Sponsor:
Information provided by (Responsible Party):
John Gonder, Lawson Health Research Institute

Brief Summary:

Primary Objectives:

To assess the efficacy of intravitreal administered Eylea in preventing visual loss in subjects with a retinal pigment epithelial detachment (PED) subtype of neovascular age-related macular degeneration (AMD) measured by mean change in BCVA at Month 12 compared to Baseline.

Secondary Objectives:

  1. To assess the safety and tolerability of repeated intravitreal administration of Eylea in subjects with the PED subtype of neovascular AMD for a period of 1 year
  2. To assess the effect of repeated intravitreal administration of Eylea on Central Subfield Thickness (CSFT), Central Subfield Volume (CSFV), and PED height and volume.
  3. To assess the effect of repeated intravitreal administration of Eylea on vision related quality of life in subjects with PED study type of neovascular AMD assessed using the NEI/VFQ-25 questionnaire

Condition or disease Intervention/treatment Phase
Retinal Pigment Epithelial Detachment Secondary to Age-related Macular Degeneration Drug: Eylea Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 37 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A 12-month, Exploratory Open-label Study of Eylea (Aflibercept) in Subjects With Retinal Pigment Epithelial Detachment Secondary to Neovascular Age-related Macular Degeneration
Study Start Date : May 2014
Actual Primary Completion Date : November 2016
Actual Study Completion Date : November 2016


Arm Intervention/treatment
Eylea
The intravitreal dose of Eylea will be 2mg (50ul) per injection. The medication will be supplied in single use vials. Given monthly for 3 months and then every 8 weeks until week 52. This is an open-label study.
Drug: Eylea
monthly injections for 3 months and then every other month to 1 year. volume administered is 0.05ml
Other Names:
  • Eylea is the brand name.
  • Aflibercept is the generic name.
  • The DIN is 02415992.




Primary Outcome Measures :
  1. efficacy of Eylea in patients with RPED [ Time Frame: baseline to month 12 ]
    visual acuity mean change from baseline compared to month 12


Secondary Outcome Measures :
  1. safety and tolerability of repeated Eylea injection [ Time Frame: period of 1 year ]
    assessment of adverse events at each visit

  2. effect of repeated Eylea injections of Central Subfield Thickness , Central Subfield Volume and PED height and volume [ Time Frame: baseline to month 12 ]
    using OCT (optical coherence tomography) thickness, volume and height will be compared from baseline to month 12

  3. effect of repeated Eyle injections on vision related quality of life [ Time Frame: baseline to month 12 ]
    using the standardized NEI/VFQ-25 questionnaire reponses will be compared from baseline to month 12



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Signed, informed consent.
  2. Men and women greater than or equal to 55 years of age.
  3. Recent development of RPED secondary to AMD.
  4. ETDRS best corrected visual acuities of 20/40 to 20/320 (letter score of 73 to 25) in the study eye.
  5. Willing and committed and able to return for all clinic visits and complete all study related procedures.

Exclusion Criteria:

  1. Any prior treatment for neovascular AMD except dietary supplements or vitamins. (for patients in the treatment naïve group only)
  2. Any prior or concomitant therapy with another investigational agent to treat neovascular AMD in the study eye.
  3. Total lesion size greater than 12 disc areas.
  4. Subretinal hemorrhage that is either 50% or more of the total lesion area or if the blood is under the fovea and is 1 or more disc areas in size in the study eye.
  5. Scar or fibrosis making up greater than 50% of the total lesion in the study eye.
  6. Scar, fibrosis or atrophy involving the center of the fovea.
  7. Presence of a retinal pigment epithelial tear.
  8. History of a vitreous hemorrhage within 4 weeks prior to initiation of the study.
  9. Presence of other causes of choroidal neovascular membrane other than AMD.
  10. History of clinical evidence of diabetic retinopathy, especially diabetic maculopathy or macular edema from other causes, including retinal vein occlusion or diabetes
  11. Prior vitrectomy surgery in the study eye.
  12. History of retinal detachment treatment in the study eye.
  13. History of macular hole in the study eye.
  14. Any intraocular/periocular surgery within 3 months of the initiation of the study.
  15. Prior trabeculectomy or filtering surgery in the study eye.
  16. Uncontrolled glaucoma, defined as a pressure greater than 25 mmHg despite treatment.
  17. Active intraocular inflammation.
  18. Active ocular/periocular infection.
  19. Any history of uveitis.
  20. Active scleritis or episcleritis.
  21. Aphakia or pseudophakia with absence of posterior capsule (unless it occurred as a result of YAG posterior capsulotomy) in the study eye.
  22. Previous radiation therapy in the region of the study eye.
  23. History of corneal transplant or corneal dystrophy in the study eye.
  24. Significant medial opacities including cataract that may interfere with visual acuity or fundus photography.
  25. Any disease or ocular condition which, in the opinion of the investigator could either increase in the risk to the subject beyond what is expected from a standard procedure of intraocular injections or which may be considered contraindicated for the use of the investigational drug (VEGF Trap).
  26. The use of long acting steroids systemically or intraocularly.
  27. Any history of allergy to Proviodine or fluorescein sodium.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02142296


Locations
Layout table for location information
Canada, Ontario
Ivey Eye Institute
London, Ontario, Canada, N6A 4V2
Sponsors and Collaborators
Lawson Health Research Institute

Layout table for additonal information
Responsible Party: John Gonder, Principal Investigator, Lawson Health Research Institute
ClinicalTrials.gov Identifier: NCT02142296     History of Changes
Other Study ID Numbers: Bayer-001-PED
First Posted: May 20, 2014    Key Record Dates
Last Update Posted: February 16, 2017
Last Verified: February 2017

Keywords provided by John Gonder, Lawson Health Research Institute:
Pigment Epithelial Detachment
Age-related Macular degeneration

Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasm Metastasis
Macular Degeneration
Dissociative Disorders
Retinal Detachment
Neoplastic Processes
Neoplasms
Pathologic Processes
Retinal Degeneration
Retinal Diseases
Eye Diseases
Mental Disorders